Keman Zhang

Keman Zhang

Auto-generated profile, based on publicly available information

Keman Zhang

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2024 in Science Immunology
Verified
Journal Article
Closed access
HTHieu Minh Ta
Hieu Minh Ta
DRDia Roy
Dia Roy
KZKeman Zhang
Keman Zhang
TATyler Alban
Tyler Alban
IJIvan Juric
Ivan Juric
LWLi Lily Wang
Li Lily Wang
Immune checkpoint blockade is a promising approach to activate antitumor immunity and improve the survival of patients with cancer. V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune checkpoint target; however, the downstream signaling mechanisms are elusive. Here, we identify leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) as a VISTA binding partner, which acts as an inhibitory receptor by engaging VISTA and suppressing T cell receptor signaling pathways. Mice with T cell–specific LRIG1 deletion developed superior antitumor responses because of expansion of tumor-specific cytotoxic T lymphocytes (CTLs) with increased effector function and survival. Sustained tumor control was associated with a reduction of quiescent CTLs (TCF1 + CD62L hi PD-1 low ) and a reciprocal increase in progenitor and memory-like CTLs (TCF1 + PD-1 + ). In patients with melanoma, elevated LRIG1 expression on tumor-infiltrating CD8 + CTLs correlated with resistance to immunotherapies. These results delineate the role of LRIG1 as an inhibitory immune checkpoint receptor and propose a rationale for targeting the VISTA/LRIG1 axis for cancer immunotherapy.

4 April 2023
Verified
Other
Open access
YVYorleny Vicioso
Yorleny Vicioso
HGHermann Gram
Hermann Gram
RBRose Beck
Rose Beck
Abhishek AsthanaAbhishek Asthana
Abhishek Asthana
KZKeman Zhang
Keman Zhang
RPReshmi Parameswaran
Reshmi Parameswaran

4 April 2023
Verified
Other
Open access
YVYorleny Vicioso
Yorleny Vicioso
HGHermann Gram
Hermann Gram
RBRose Beck
Rose Beck
Abhishek AsthanaAbhishek Asthana
Abhishek Asthana
KZKeman Zhang
Keman Zhang
RPReshmi Parameswaran
Reshmi Parameswaran

4 April 2023
Verified
Other
Open access
YVYorleny Vicioso
Yorleny Vicioso
HGHermann Gram
Hermann Gram
RBRose Beck
Rose Beck
Abhishek AsthanaAbhishek Asthana
Abhishek Asthana
KZKeman Zhang
Keman Zhang
RPReshmi Parameswaran
Reshmi Parameswaran
Supp. Fig. 2 BAFF induces up-regulation of survival pathways. A, PT-3 ALL cells were cultured with VAY736 (20 μg/mL) and recombinant BAFF (0.2 μg/mL) for 72 hours and the expression levels of proliferation genes (p100, p52) and survival genes (Pim-1, BclÃ,­xl, and A-1) were measured by Western blotting. GAPDH was used as protein loading control.

4 April 2023
Verified
Other
Open access
YVYorleny Vicioso
Yorleny Vicioso
HGHermann Gram
Hermann Gram
RBRose Beck
Rose Beck
Abhishek AsthanaAbhishek Asthana
Abhishek Asthana
KZKeman Zhang
Keman Zhang
RPReshmi Parameswaran
Reshmi Parameswaran

4 April 2023
Verified
Other
Open access
YVYorleny Vicioso
Yorleny Vicioso
HGHermann Gram
Hermann Gram
RBRose Beck
Rose Beck
Abhishek AsthanaAbhishek Asthana
Abhishek Asthana
KZKeman Zhang
Keman Zhang
RPReshmi Parameswaran
Reshmi Parameswaran
Supp. Fig. 1 ALL sample characteristics. A, Summary data from 11 adults and 5 pediatric ALL patients. Genetic and diagnostic information was provided by clinical pathologist Rose Beck at University Hospitals Medical Center (UHMC). BAFF-R expression was determined by FACs analysis of gated CD19+, CD10+ cells (each sample represents an independent experiment). B, mRNA BAFF-R expression levels in ALL cells relative to GAPDH (mean {plus minus} SEM of 3 technical replicates). C, Representative FACs analysis (left) and percentages (right) of BAFF-R expression in PBMCs, gated B-cells (CD19+CD3-), T-cells (CD3+, CD19-, CD56-), and NK cells (CD56+, CD3-). The data represent the mean {plus minus} SEM of 3 technical replicates of 4 healthy donors from 2 independent experiments. D, Viability of relapse PhÃ,­ (PT-2) and drug resistant Ph+ (PTÃ,­3 & PTÃ,­4) ALL cells after treatment with either vincristine (2.5 nM) or nilotinib (300 nM) at the indicated time points. The data represent the mean {plus minus} SEM of 4 independent experiments with 3 technical replicates.